BusinessSienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic DermatitisBy Nasdaq OMXMar 12, 2018, 10:05 AM UTC
BusinessSienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125By Nasdaq OMXFeb 14, 2018, 2:05 PM UTC
